This is a pricing-structure change , not a guaranteed price cut
A.Gonzalez-MatiasL
18% of US respondents reported taking prescription drugs for weight loss in 2025, up from 10% in 2024 Source: Euromonitors Voice of the Consumer: Health and Nutrition Survey, fielded February 2024 Legacy weight loss brands turn their attention towards GLP-1 consumers Heritage weight loss companies are shifting focus to accommodate the GLP-1 consumer
4750 To date, there has only been 1 randomized crossover study to investigate comparative effects of different medications for management of PBH after RYGB, using mixed meal tolerance test and CGM
Side Effects & Safety AOD-9604 has a favorable safety profile supported by clinical trial data: FDA GRAS status: The compound received GRAS status as a food ingredient, reflecting some regulatory safety evaluation, though this is not equivalent to drug safety approval Clinical trial tolerability: Phase I and Phase II clinical trials conducted by Metabolic Pharmaceuticals generally found AOD-9604 well-tolerated at studied doses Injection site reactions: Minor discomfort with subcutaneous administration Headache and nausea: Reported in some clinical trial subjects No significant metabolic effects: Blood glucose, insulin, HbA1c, and IGF-1 were not significantly altered in clinical studies, which distinguishes it favorably from full GH Long-term safety data for subcutaneous use in the research community context (typically higher and more frequent dosing than clinical trials) is limited
/assets/images/provider/photos/2805921.jpeg)
